샘플 요청 목록

 카트 문의
시장보고서
상품코드
1790389

세계의 말초동맥질환 시장 규모, 점유율, 동향 분석 보고서 : 기기 유형별, 해부학적 부위별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Peripheral Artery Disease Market Size, Share & Trends Analysis Report By Services (Endovascular Devices, Surgical Devices), By Anatomical Site (Aortoiliac, Femoropopliteal), By End-use, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 90 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

말초동맥질환 시장 개요

세계 말초동맥질환 시장 규모는 2024년 73억 달러로 평가되었습니다. 2033년에는 113억 달러에 달하고, 2025-2033년 연평균 5.2% 성장할 것으로 예측됩니다. 질병 부담 증가, 지속적인 기술 발전, 인구 고령화라는 복합적인 요인이 말초동맥질환(PAD) 산업을 견인하고 있습니다.

충족되지 않은 임상적 요구와 진화하는 치료 능력이 만나면서 의료 현장 전반 수요가 가속화되고 있습니다. 당뇨병과 담배의 유병률 증가는 여전히 시장을 이끄는 기본 동력이 되고 있습니다. 두 위험인자 모두 PAD의 핵심 병리학적 기전인 죽상동맥경화증의 진행에 직접적으로 기여합니다. 당뇨병 유병률은 전 세계적으로 증가 추세에 있으며, 특히 도시 고령화 사회에서 두드러지고, 저소득 국가에서는 흡연이 여전히 만연해 있기 때문에 PAD의 유병률은 계속 증가하고 있습니다.

2025년 3월 ACC 학회에서 발표된 Intermountain Health의 연구에 따르면, 증상이 있는 말초동맥질환 환자 중 가이드라인에 따른 치료를 받은 환자는 여성 29.6%, 남성 33.5%에 불과한 것으로 나타났습니다. 추적한 7,522명의 환자 중 사망률이 50%를 넘어 진단과 치료의 심각한 격차를 드러냈습니다. 비슷한 발표율에도 불구하고, 여성은 최적의 치료를 받을 가능성이 낮았습니다. 이 연구는 스크리닝 프로토콜의 개선과 PAD 관리에 대한 강조의 필요성을 강조했습니다.

혈관 내 치료 기술의 급속한 혁신은 치료 전략을 재구성하고 시장의 모멘텀을 강화하고 있습니다. 약물 코팅 풍선, 동맥절제술 시스템, 생체 흡수성 스텐트 등 차세대 도구는 효과 향상, 합병증 감소, 회복 시간 단축을 가져옵니다. 이러한 솔루션은 복잡한 병변을 정확하게 치료하는 동시에 재협착이나 재수술의 필요성을 줄이기 위해 점점 더 많이 선호되고 있습니다. 2025년 3월, Scientific Reports에 게재된 연구에서는 혈관 내 치료 중 스텐트 삽입 정확도를 향상시키는 딥러닝 모델 DBMedDet이 발표되었습니다. 높은 정확도(MAP 0.841)와 실시간 검출(127 FPS)로 관상동맥, 말초혈관, 뇌혈관 각 사례에서 스텐트 경계를 식별하는 데 있어 YOLO 모델을 능가하는 결과를 보였습니다.

인구의 고령화는 PAD 중재술 시장 잠재력을 더욱 증폭시키고 있으며, 65세 이상은 현저히 높은 위험에 직면해 있습니다. 노화와 관련된 동맥경화 및 동반 질환의 축적은 이 인구 집단을 특히 취약하게 만듭니다. 2025년 3월, 에이징 저널(Aging Journal)은 Long Life Family Study의 결과를 발표했는데, 장수 가족은 PAD의 위험이 현저히 낮다는 것을 보여주었습니다. 이들 가문의 자손의 PAD 유병률은 예상치인 12% 대비 1%에 불과했습니다. 연구팀은 이 결과를 보호 유전형질과 건강한 혈관 프로파일과 연결하여 PAD 저항성과 관련이 있을 수 있는 4개의 유전체 영역을 확인했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계의 말초동맥질환 시장 변수, 동향 및 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 말초동맥질환 시장 분석 툴
    • 산업 분석 - Porter의 Five Forces 분석
    • PESTEL 분석

제4장 말초동맥질환 시장 : 기기 유형별, 추정 및 동향 분석

  • 말초동맥질환 시장 : 기기 유형 대시보드
  • 말초동맥질환 시장 : 기기 유형 변동 분석
  • 말초동맥질환 시장 규모와 예측·동향 분석(기기 유형별, 2021-2033년)
  • 혈관내 기기
  • 외과용 기기

제5장 말초동맥질환 시장 : 해부학적 부위별, 추정 및 동향 분석

  • 말초동맥질환 시장 : 해부학적 부위 대시보드
  • 말초동맥질환 시장 : 해부학적 부위 변동 분석
  • 말초동맥질환 시장 규모와 예측·동향 분석(해부학적 부위별, 2021-2033년)
  • 대동맥
  • 대퇴골
  • 경골

제6장 말초동맥질환 시장 : 최종 용도별, 추정 및 동향 분석

  • 말초동맥질환 시장 : 최종 용도 대시보드
  • 말초동맥질환 시장 : 최종 용도 변동 분석
  • 말초동맥질환 시장 규모와 예측·동향 분석(최종 용도별, 2021-2033년)
  • 병원
  • 외래시설
  • 기타

제7장 말초동맥질환 시장 : 국, 기기 유형, 해부학적 부위, 최종 용도에 의한 지역별, 추정 및 동향 분석

  • 세계의 말초동맥질환 시장 : 지역별 대시보드
  • 시장 규모와 예측 동향 분석, 2021-2033년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 스웨덴
    • 노르웨이
    • 덴마크
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 태국
    • 한국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 사우디아라비아
    • 남아프리카공화국
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 제조업체에 의한 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 벤더 구도
    • 주요 유통업체와 채널 파트너 리스트
    • 주요 기업의 시장 점유율 분석, 2024년
    • BD
    • Bentley InnoMed
    • Scitech Medical
    • Abbott Laboratories
    • Boston Scientific Corporation
    • WL Gore & Associates, Inc.
    • Medtronic
    • Cook
    • Terumo Corporation
    • iVascular
    • Getinge AB
    • BIoTronik SE & Co KG
LSH 25.08.20

Peripheral Artery Disease Market Summary

The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. The intersecting forces of rising disease burden, continuous technological advancement, and demographic aging drive the peripheral artery disease (PAD) industry.

This alignment of unmet clinical needs with evolving therapeutic capabilities accelerates demand across care settings. The growing prevalence of diabetes and tobacco use remains a foundational force driving the market. Both risk factors contribute directly to the progression of atherosclerosis, the core pathological mechanism behind PAD. With diabetes rates climbing globally-particularly in aging, urban populations-and smoking still widespread in lower-income countries, the incidence of PAD continues to rise.

In March 2025, an Intermountain Health study presented at the ACC conference revealed that only 29.6% of women and 33.5% of men with symptomatic peripheral artery disease received full guideline-directed therapy. Among 7,522 patients tracked, the mortality rate exceeded 50%, underscoring severe gaps in diagnosis and treatment. Despite similar referral rates, women were less likely to receive optimal care. The study emphasized the need for improved screening protocols and focused PAD management.

Rapid innovation in endovascular technologies is reshaping treatment strategies and reinforcing market momentum. Next-generation tools such as drug-coated balloons, atherectomy systems, and bioresorbable stents offer improved efficacy, fewer complications, and shorter recovery times. These solutions are increasingly favored for treating complex lesions precisely while reducing restenosis and the need for repeat interventions. In March 2025, a study in Scientific Reports introduced DBMedDet, a deep-learning model that improved stent placement accuracy during endovascular procedures. With high precision (mAP 0.841) and real-time detection (127 FPS), it outperformed YOLO models in identifying stent boundaries across coronary, peripheral, and cerebrovascular cases.

Population aging further amplifies the market potential for PAD interventions, with individuals over 65 facing significantly elevated risk. Age-related arterial stiffening and the accumulation of comorbidities make this demographic especially vulnerable. In March 2025, the Aging Journal published findings from the Long Life Family Study showing individuals from long-lived families have a significantly lower risk of PAD. PAD prevalence among offspring of these families was only 1%, versus an expected 12%. Researchers linked this to protective genetic traits and healthier vascular profiles, identifying four genomic regions potentially tied to PAD resistance.

Global Peripheral Artery Disease Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peripheral artery disease market report based on device type, anatomical site, end use, and region:

  • Device Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Endovascular Devices
  • Surgical Devices
  • Anatomical Site Outlook (Revenue, USD Million, 2021 - 2033)
  • Aortoiliac
  • Femoropopliteal
  • Tibial
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Outpatient Facilities
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Device Type
    • 1.2.2. Anatomical Site
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Device Type Segment
    • 2.2.2. Anatomical Site Segment
    • 2.2.3. End Use Segment
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Peripheral Artery Disease Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of diabetes and smoking
      • 3.2.1.2. Advancements in endovascular technologies
      • 3.2.1.3. Growing elderly population and PAD risk
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of advanced revascularization procedures
      • 3.2.2.2. Limited access to PAD treatment in low-income regions
  • 3.3. Peripheral Artery Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Peripheral Artery Disease Market: Device Type Estimates & Trend Analysis

  • 4.1. Peripheral Artery Disease Market: Device Type Dashboard
  • 4.2. Peripheral Artery Disease Market: Device Type Movement Analysis
  • 4.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by Device Type, 2021 - 2033 (USD Million)
  • 4.4. Endovascular Devices
    • 4.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.5. Surgical Devices
    • 4.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 5. Peripheral Artery Disease Market: Anatomical Site Estimates & Trend Analysis

  • 5.1. Peripheral Artery Disease Market: Anatomical Site Dashboard
  • 5.2. Peripheral Artery Disease Market: Anatomical Site Movement Analysis
  • 5.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by Anatomical Site, 2021 - 2033 (USD Million)
  • 5.4. Aortoiliac
    • 5.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5. Femoropopliteal
    • 5.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.6. Tibial
    • 5.6.1. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. Peripheral Artery Disease Market: End Use Estimates & Trend Analysis

  • 6.1. Peripheral Artery Disease Market: End Use Dashboard
  • 6.2. Peripheral Artery Disease Market: End Use Movement Analysis
  • 6.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by End Use, 2021 - 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. Outpatient Facilities
    • 6.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Peripheral Artery Disease Market: Regional Estimates & Trend Analysis by Country, Device Type, Anatomical Site & End Use

  • 7.1. Global Peripheral Artery Disease Market: Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2021 - 2033
  • 7.3. North America
    • 7.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Regulatory framework/ reimbursement structure
      • 7.3.4.3. Competitive scenario
      • 7.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.9. Denmark
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework/ reimbursement structure
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.7.3. South Africa
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. BD
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bentley InnoMed
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Scitech Medical
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Abbott Laboratories
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Boston Scientific Corporation
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. W. L. Gore & Associates, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Medtronic
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Cook
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Terumo Corporation
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. iVascular
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Getinge AB
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. Biotronik SE & Co KG
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제